Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MICHAEL TETZLAFF and JEFFREY E GERSHENWALD.
MICHAEL TETZLAFF
Connection Strength
2.590
JEFFREY E GERSHENWALD
  1. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
    View in: PubMed
    Score: 0.215
  2. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020 11; 31(11):1569-1579.
    View in: PubMed
    Score: 0.184
  3. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.172
  4. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835.
    View in: PubMed
    Score: 0.163
  5. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868.
    View in: PubMed
    Score: 0.160
  6. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.159
  7. Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
    View in: PubMed
    Score: 0.143
  8. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.128
  9. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.
    View in: PubMed
    Score: 0.055
  10. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
    View in: PubMed
    Score: 0.055
  11. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.
    View in: PubMed
    Score: 0.054
  12. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.052
  13. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.051
  14. Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. Arch Pathol Lab Med. 2021 12 01; 145(12):1505-1515.
    View in: PubMed
    Score: 0.051
  15. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.050
  16. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.049
  17. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep. 2021 04 27; 11(1):9043.
    View in: PubMed
    Score: 0.048
  18. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
    View in: PubMed
    Score: 0.047
  19. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.044
  20. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
    View in: PubMed
    Score: 0.044
  21. Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593.
    View in: PubMed
    Score: 0.043
  22. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
    View in: PubMed
    Score: 0.043
  23. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
    View in: PubMed
    Score: 0.042
  24. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
    View in: PubMed
    Score: 0.041
  25. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.041
  26. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.041
  27. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.039
  28. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
    View in: PubMed
    Score: 0.038
  29. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.
    View in: PubMed
    Score: 0.037
  30. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.036
  31. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
    View in: PubMed
    Score: 0.036
  32. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.035
  33. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.035
  34. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044.
    View in: PubMed
    Score: 0.034
  35. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.033
  36. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.031
  37. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.031
  38. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.